|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL.
|
31705818 |
2019 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that ALK-positivity in cutaneous ALCL does not necessarily imply systemic disease.
|
29057463 |
2018 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK has now been shown to play a role in the pathogenesis of several cutaneous malignancies, including secondary cutaneous systemic anaplastic large-cell lymphoma (ALCL) and primary cutaneous ALCL, melanoma, spitzoid tumors, epithelioid fibrous histiocytoma, Merkel cell carcinoma, and basal cell carcinoma.
|
28895885 |
2017 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The expression of CD30 and ALK1 with ALK gene rearrangement raised the possibility of three diagnoses: a primary cutaneous anaplastic large cell lymphoma (ALCL), a cutaneous inflammatory myofibroblastic tumor (IMT), an AFH of the skin associated with ALK gene rearrangement and CD30 positivity.
|
24666231 |
2014 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous anaplastic large cell lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders.
|
22773605 |
2013 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma--is it a new variant?
|
22565437 |
2012 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry results indicated that Id2 was expressed strongly in 21 of 27 (78%) ALCL tumors (79% anaplastic lymphoma kinase [ALK]-negative and 75% ALK-positive), in 5 of 10 (50%) extranodal natural killer/T (NK/T)-cell lymphomas of the nasal type, in 2 of 8 (25%) cutaneous ALCLs, in 2 of 9 (22%) enteropathy type T-cell lymphomas, in 1 of 5 (20%) peripheral T-cell lymphomas not otherwise specified, and in 1 of 8 (13%) T-cell prolymphocytic leukemias.
|
18085637 |
2008 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, within this heterogenous group of neoplasms, some have a more favorable prognosis, such as ALK-positive anaplastic large-cell leukemia (ALCL) and primary cutaneous ALCL, and some have ultimately fatal courses with standard chemotherapy programs (e.g., hepatosplenic gammadelta T-cell lymphomas).
|
19074097 |
2008 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative.
|
18670345 |
2008 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30 signaling activates NF-kappaB in cell lines derived from cutaneous ALCL but not anaplastic lymphoma kinase (ALK)-positive systemic ALCL in which growth arrest occurs through cell cycle inhibitor p21WAF1/Cip1.
|
17387297 |
2007 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ALK- lymphomas with anaplastic morphology showed extra nonrearranged anaplastic lymphoma kinase gene loci (P=0.004) due to trisomy 2 irrespective of the following factors: B or T/null phenotype (P=0.315), diagnostic categories of systemic or cutaneous ALCL or the above-mentioned B-cell lymphomas (P=0.131), and CD30 positivity by immunohistochemistry (P=1.000).
|
15475930 |
2005 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In NHLs, WT1 was positive in 4 of 5 (80%) Burkitt lymphomas, 9 of 12 (75%) ALK-positive ALCLs, 3 of 6 (50%) lymphoblastic lymphomas (2 of 4 T-cell, 1 of 2 B-cell), 14 of 31 (45%) ALK-negative ALCLs, 6 of 18 (33%) DLBCLs, and 1 of 6 (17%) cutaneous ALCLs.
|
15894924 |
2005 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, primary cutaneous ALCL that are ALK negative have a better overall survival.
|
15713979 |
2005 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation.
|
15214912 |
2004 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a screen for variant ALK gene fusions, we identified two ALCL that were negative for NPM-ALK by reverse transcriptase-polymerase chain reaction, but were positive for cytoplasmic ALK with both polyclonal and monoclonal antibodies to the ALK tyrosine kinase domain, consistent with ALK deregulation by an alteration other than the t(2;5) Case 1 was a T-lineage nodal and cutaneous ALCL in a 52-year-old woman, and Case 2 was a T-lineage nodal ALCL in a 12-year-old girl.
|
10702393 |
2000 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the use of molecular and clinical criteria, 3 entities of ALCL have been identified: primary systemic anaplastic lymphoma kinase (ALK)(+) ALCL, primary systemic ALK(-) ALCL, and primary cutaneous ALCL.
|
11090048 |
2000 |
|
Primary Cutaneous Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis.
|
9415224 |
1997 |